All In Biotech

Drug Trial Radar · NCT04046484

PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients

A Prospective, Multicentric, Randomized, Double Blind, Parallel, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: May 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jan 19, 2018

Primary completion

Apr 12, 2019

Study completion Jun 30, 2019

Sponsor

Lead sponsor
Pharmazz, Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in patients of acute ischemic stroke.

Conditions

  • Acute Stroke
  • Cerebral Ischemia

Interventions

  • Normal Saline along with standard treatmentDrug

    The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.

  • PMZ-1620 along with standard treatmentDrug

    PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of PMZ-1620 related adverse eventsTime frame: 90 days
  2. Number of patients not receiving full treatmentTime frame: 90 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Paras Hospital

    Gūrgaon, India

  • Nizam's Institute of Medical Sciences

    Hyderabad, India

  • Sanjay Gandhi Post Graduate Institute of Medical Sciences

    Lucknow, India

  • Dayanand Medical College & Hospital

    Ludhiana, India

  • Department of Neurology, Christian Medical College and Hospital

    Ludhiana, India

  • New Era Hospital & Research Institute

    Nagpur, India

  • All India Institute of Medical Sciences

    New Delhi, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.